The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Bosutinib (BOS) and letrozole (LET) versus LET alone as first-line treatment in postmenopausal women with advanced breast cancer (ABC).
L. Chow
No relevant relationships to disclose
B. Xu
No relevant relationships to disclose
L. Y. Dirix
No relevant relationships to disclose
B. Moy
No relevant relationships to disclose
E. Leip
Employment or Leadership Position - Pfizer
N. Bardy-Bouxin
Employment or Leadership Position - Pfizer
Stock Ownership - Pfizer
L. Duvillie
Employment or Leadership Position - Pfizer
T. Sarosiek
Honoraria - Pfizer
Research Funding - Pfizer